Enzyvant, a biopharmaceutical company focused on developing therapies for people with rare diseases, announced yesterday that it has named George O Elston as its chief financial officer and head of corporate development.
Elston is a veteran biopharmaceutical executive with more than 25 years' experience leading global business and financial operations for start-up, private and public companies. He most recently served as president and chief executive officer of 2X Oncology Inc and was earlier the chief financial officer at Juniper Pharmaceuticals Inc. Currently he is a trustee and audit committee chairman for the Deutsche Bank AG - DBX Trust.
Alvin Shih, MD, chief executive officer of Enzyvant, said, 'George has a tremendous background ideally suited to Enzyvant. His broad-based experience and excellent track record speak to his ability to bring immense value as we look forward to achieving our near-term milestones, including completion of the rolling RVT-802 BLA filing and initiation of the RVT-801 clinical study.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval